3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gynecologic
1
Conditions
Ovarian Neoplasms
15
Uterine Cervical Neoplasms
7
Endometrial Neoplasms
7
Fallopian Tube Neoplasms
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Carcinoma, Renal Cell
4
Carcinoma, Ovarian Epithelial
4
Pancreatic Neoplasms
3
Melanoma
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neuroendocrine Tumors
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Uterine Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Teratoma
1
Interventions
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Pathologic Complete Response
×
Gynecologic
×
Clear all
NCT01844986
2025-12-10
SOLO-1
AstraZeneca
Phase 3
Active not recruiting
450 enrolled
18 charts
1 FDA